TheraRadar
← Back
Data updated: Mar 29, 2026

HAINAN POLY PHARM

OncologyInfectious DiseaseDermatology
Generics

HAINAN POLY PHARM is a generic drug manufacturer focused on Oncology, Infectious Disease, Dermatology.

2018
Since
16
Drugs
-
Trials
263
Approved (2yr)

Key Drugs

CISATRACURIUM BESYLATE PRESERVATIVE FREE
cisatracurium besylate
cholinergic receptor · 2012

Top Drug Revenues Pro

Loading...

Revenue Over Time Pro

Loading...

Recent Activity

BRIVARACETAM 2026-02-23
BRIVARACETAM 2026-02-23
BRIVARACETAM 2026-02-23
BRIVARACETAM 2026-02-23
BRIVARACETAM 2026-02-23
BRIVARACETAM 2026-02-23
BRIVARACETAM 2026-02-23
BRIVARACETAM 2026-02-23
SEC Filings Pro
Loading...

Therapeutic Areas

Score weights: Approved drugs ×3, Phase 3 ×2, Phase 2 ×1, Phase 1 ×0.5

Oncology 33%
2 drugs
Infectious Disease 33%
2 drugs
Dermatology 17%
1 drugs
Neurology 17%
1 drugs

Pipeline Forecast

Loading...

Upcoming Trial Milestones Pro

Loading...

Patent Cliff Pro

Loading...

Competitors by Therapeutic Area

Pfizer big-pharma
Oncology, Infectious Disease, Dermatology
Baxter specialty
Infectious Disease, Oncology, Dermatology
AbbVie big-pharma
Oncology, Neurology, Infectious Disease
GSK big-pharma
Infectious Disease, Oncology, Neurology
Eli Lilly big-pharma
Oncology, Neurology, Dermatology